# A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

> **NCT01441232** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LX4211
- **DRUG:** Januvia®

## Key facts

- **NCT ID:** NCT01441232
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441232, "A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01441232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*